Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 4/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.50 |
| ▸ | RELA | Q04206 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 5/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL23035299 | 0.99 | ALDH1A1 (0.58) | ALDH1A1MAPTRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL17777317 | 0.86 | ALDH1A1 (0.52) | ALDH1A1MAPTNPC1SMN1; SMN2CYP3A4 | |
| SCHEMBL14705885 | 0.85 | ALDH1A1 (0.40) | ALDH1A1MAPTRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL16692414 | 0.85 | ALDH1A1 (0.46) | ALDH1A1MAPTKMT2A | |
| SCHEMBL16692415 | 0.85 | ALDH1A1 (0.46) | ALDH1A1MAPTRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL14706051 | 0.84 | ALDH1A1 (0.44) | ALDH1A1MAPTRAB9ANPC1MEN1 | |
| Hydrochloric Acid SCHEMBL23035265 | 0.84 | ALDH1A1 (0.39) | ALDH1A1MAPTRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL23047488 | 0.83 | KMT2A (0.42) | ALDH1A1RAB9ANPC1MEN1KMT2A | |
| SCHEMBL14705943 | 0.83 | DDX3X (0.44) | ALDH1A1RAB9ANPC1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL23035227 | 0.83 | ALDH1A1 (0.43) | ALDH1A1MAPTRAB9ANPC1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2742019-B1 | N1-CYCLIC AMINE-N5-SUBSTITUTED PHENYL BIGUANIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | IMMUNOMET THERAPEUTICS INC (US) | 2021-03-03 | — | — | EP | claimed |
| EP-2742019-B1 | N1-CYCLIC AMINE-N5-SUBSTITUTED PHENYL BIGUANIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | IMMUNOMET THERAPEUTICS INC (US) | 2021-03-03 | — | — | EP | disclosed |
| EP-2742019-B1 | N1-CYCLIC AMINE-N5-SUBSTITUTED PHENYL BIGUANIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | IMMUNOMET THERAPEUTICS INC (US) | 2021-03-03 | — | — | EP | disclosed |
| US-9540325-B2 | N1-cyclic amine-N5-substituted phenyl biguanide derivatives, methods of preparing the same and pharmaceutical composition comprising the same | ImmunoMet Therapeutics, Inc. (US) | 2017-01-10 | — | — | US | disclosed |
| US-9540325-B2 | N1-cyclic amine-N5-substituted phenyl biguanide derivatives, methods of preparing the same and pharmaceutical composition comprising the same | ImmunoMet Therapeutics, Inc. (US) | 2017-01-10 | — | — | US | disclosed |
| US-20140179660-A1 | N1-Cyclic Amine-N5-Substituted Phenyl Biguanide Derivatives, Methods of Preparing the Same and Pharmaceutical Composition Comprising the Same | HANALL BIOPHARMA CO., LTD. (KR) | 2014-06-26 | — | — | US | disclosed |
| US-20140179660-A1 | N1-Cyclic Amine-N5-Substituted Phenyl Biguanide Derivatives, Methods of Preparing the Same and Pharmaceutical Composition Comprising the Same | HANALL BIOPHARMA CO., LTD. (KR) | 2014-06-26 | — | — | US | disclosed |
| WO-2013022278-A2 | N1-CYCLIC AMINE-N5-SUBSTITUTED PHENYL BIGUANIDE DERIVATIVES, METHODS OF PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HANALL BIOPHARMA CO., LTD. (KR) | 2013-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179660-A1 | N1-Cyclic Amine-N5-Substituted Phenyl Biguanide Derivatives, Methods of Preparing the Same and Pharmaceutical Composition Comprising the Same | GCKR, PRKAG1, GPR119 | ALDH1A1 2347/4885MAPT 2616/4885RAB9A 1511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.